Gilead Sciences’ cancer therapy Trodelvy did not improve overall survival for patients with advanced bladder cancer compared to chemotherapy, threatening its accelerated approval. This is the drug’s second disappointing data readout after a failed lung cancer study earlier this year. Trodelvy targets the TROP-2 protein on cancer cells and was approved for triple-negative breast cancer in 2020. While Trodelvy did not show a statistically significant survival benefit, it did show numerical improvement. However, the drug had a higher number of deaths due to adverse events compared to chemotherapy. The recent trial failures have impacted Trodelvy’s ability to compete with other TROP-2-targeting drugs like datopotamab deruxtecan.
Source link
Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer
